Advancing Medication Safety in Cancer Care

National Medication Safety Summit: Towards a National Approach
Friday, 9th October 2015

Patricia Heckmann - NCCP
Strategic Direction for Cancer Services

- NCCP - established 2007
- National Cancer Registry in place under legislation.
- Reorganisation of services:
  - 8 cancer centres for diagnosis and treatment
  - 6 providers for radiation oncology
  - 26 hospitals for systemic therapy
Cancer Continuum

SOURCE: Adapted from National Cancer Institute figure on the “Cancer Control Continuum” (NCI, 2013b).
Why have a Cancer Control Programme?

33,000 people receiving chemotherapy each year

50% increase projected by 2025

<table>
<thead>
<tr>
<th>Projected increase</th>
<th>2015</th>
<th>2020</th>
<th>2025</th>
<th>2030</th>
<th>2035</th>
<th>2040</th>
<th>% increase from 2010 to 2040</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Cancer Cases</td>
<td>31,330</td>
<td>35,864</td>
<td>40,860</td>
<td>46,070</td>
<td>51,223</td>
<td>55,991</td>
<td>97%</td>
</tr>
</tbody>
</table>
Medical Oncology Chemotherapy Activity 2025 NCRI projection of 45% increase
Haemato-Oncology Chemotherapy Activity 2025 NCRI projection of 45% increase
Systemic Therapy Programme Scope

### Designated Cancer Centres

1. Mater Misericordiae Hospital
2. St. Vincent’s University Hospital
3. Beaumont Hospital
4. St. James's Hospital
5. Cork University Hospital
6. Waterford Regional Hospital
7. Mid-Western Regional Hospital Limerick
8. University College Hospital Galway

### Centres with Medical Oncology/Haematology Consultants

1. Letterkenny General Hospital
2. Adelaide and Meath Hospital, Tallagh
3. Midlands Regional Hospital, Tullamore
4. Mercy University Hospital, Cork
5. Sligo General Hospital

### Centres with visiting or part time Medical Oncologist/Haematology Consultants

1. Naas General Hospital
2. South Infirmary/Victoria University Hospital
3. St. Luke's Hospital, Dublin
4. Kerry General Hospital
5. South Tipperary General, Clonmel
6. Mayo General Hospital
7. Portiuncula Hospital, Ballinasloe
9. Wexford General Hospital
10. Connolly Hospital, Blanchardstown
11. Cavan General Hospital
12. Our Lady of Lourdes Hospital, Drogheda

### Paediatric hospital

1. Our Lady's Children's Hospital Crumlin
Patient Pathway

PRESENTATION
- GP
- Emergency Department
- Screening
- Other hospital specialist

REFERRAL

HOSPITAL SPECIALIST ASSESSMENT

DIAGNOSIS

TREATMENT

FOLLOWUP/SURVIVORSHIP

END OF LIFE
NCCP Systemic Therapy Programme

Key drivers:
• Quality & Safety
• Access & Facilitators
• Coordination & Leadership

NCCP Quality & Safety

- NCCP Oncology Medication Safety review
- Drug protocols
- Medical Oncology Clinical Information System (MOCIS)
- Patient Consent
- KPIs
- Standardised datasets
- Patient Experience Survey
NCCP Oncology Medication Safety review

• Steering committee 2012
• Project team
• Methodology
  – Self administered questionnaire
  – Site visit
• Pilot study – Sept 2012
• Review completed May 2013
NCCP Oncology Medication Safety review

- Published 2014
- 93 recommendations
  - 13 national / 80 local
  - Mapped to HIQA’s Better Safer Healthcare Standards
NCCP Oncology Medication Safety review

- Governance – risk management
- Chemotherapy Protocols
- Chemotherapy Ordering and Prescribing
- Chemotherapy Orders and Prescription Checking
- Intrathecal Chemotherapy
- Pharmacy – Chemotherapy Preparation, Labelling and Record Keeping
- Handling, Disposal and Storage of Cytotoxics
Implementation

- Hospital status report
- Teleconference with each hospital
- Implementation status report
  - Dec 2014
  - July 2015
- www.hse.ie/nccponcnsafety review
NCCP Oncology Medication Safety review

- Implemented
- Underway
- Not started
- Not applicable
<table>
<thead>
<tr>
<th>Recommendations on risk</th>
<th>HIQA framework</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rec 5</strong></td>
<td>In line with national policy all units are encouraged to have a written policy in place on incident reporting (HSE, 2008) and open disclosure (HSE, 2013). Services are encouraged to continue with routine reporting of all medication safety incidents, including near misses.</td>
</tr>
<tr>
<td><strong>Rec 6</strong></td>
<td>The medical oncology and haematology services should actively engage with hospital risk management and quality improvement. Consideration should be given to regular scheduled multidisciplinary meetings, with risk management and supported by senior management, to discuss medication safety reports, review recurring trends and identify areas for improvement.</td>
</tr>
</tbody>
</table>
### Recommendations on intrathecal chemotherapy

The chemotherapy ordering and prescribing recommendations in 3.10.2 also apply to intrathecal chemotherapy prescribing/ordering.

| Rec 68 | All hospitals administering intrathecal chemotherapy should have the following policies in place:  
- A policy for the prescribing, preparation, delivery, storage and administration of intrathecal chemotherapy  
- A policy on the dilution of vinca alkaloids. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rec 69</td>
<td>Intrathecal chemotherapy should always be stored in a different area to intravenous chemotherapy.</td>
</tr>
<tr>
<td>Rec 70</td>
<td>Intravenous chemotherapy should always be given at a different time to intrathecal chemotherapy.</td>
</tr>
<tr>
<td>Rec 71</td>
<td>The NCCP to lead on the development of national intrathecal polices to inform the content of these local hospital policies.</td>
</tr>
</tbody>
</table>
NCCP Oncology Medication Safety review

• National working groups:
  – Built environment
  – Intrathecal chemotherapy
  – Neurotoxins
  – Oral chemotherapy
  – Competencies
  – Medical Oncology Clinical Information System
NCCP Oncology Medication Safety Review

The NCCP published its Oncology Medication Safety Review Report in January 2014. The report presented the findings from the NCCP Oncology Medication and Safety review which was conducted across the 26 hospitals in Ireland involved in the administration of systemic cancer therapy in adults and children. The aim of the review was to assess the oncology medication policies and practices in day units nationally, from a patient safety and quality perspective. The report made a total of 93 recommendations. More information will be provided here shortly.

The report is available to download below.

NCCP Oncology Medication Safety Review Report.pdf (size 1.3 MB)

Implementation Status Reports:

NCCP Oncology Medication Safety Review Implementation Status Report (March-July 2014) (244KB)
NCCP Quality & Safety

- NCCP Oncology Medication Safety review – 2014
- Drug protocols
- Medical Oncology Clinical Information System (MOCIS)
- Patient Consent
- KPIs
- Standardised datasets
- Patient Experience Survey
National drug protocols

• Collaborative approach
• Agreed and published on line
• Supports
  – Standardisation of practice
  – Evidence based medicine
  – Patient Safety
  – Medical Oncology Clinical Information System
  – Clinical audit
  – “Money Follows the Patient” funding
NCCP Chemotherapy Protocols

The HSE National Cancer Control Programme is developing Chemotherapy Protocols to support safe, evidence-based and cost-effective cancer treatment for all Irish cancer patients. These protocols are developed under the guidance of Medical Consultants involved in the treatment of patients with cancer with input from nursing staff, pharmacists and other healthcare professionals.

Clinicians using these drug protocols to provide treatment for patients will be solely responsible for verifying the doses, providing the prescriptions and administering the medications described in the protocols, according to acceptable standards of care. Use of these protocols is the responsibility of the treating clinician and is subject to the HSE’s Website Disclaimer.

The format and content of the protocols are reviewed and updated on a periodic basis. The date of last revision of each protocol is included at the end of the protocol and on the website. Additional protocols will be added to this site over time. Please email any comments or feedback on these protocols to oncologydrugs@cancercontrol.ie.

NCCP Chemotherapy Protocol

Pertuzumab + Trastuzumab + DOCETaxel

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Protocol Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertuzumab is indicated in combination with trastuzumab and DOCETaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.</td>
<td>C50</td>
<td>00204a</td>
</tr>
</tbody>
</table>

ELIGIBILITY:

- Indications as above.
- HER-2-positive tumour status, defined as a score of 3+ by immuno histochemistry (IHC) and/or a ratio of ≥ 2.0 by in situ hybridisation (ISH) assessed by a validated test.
MOCIS

- An EPR for systemic therapy cancer services
- A single point of access offering a holistic overview of a patient
- Enhanced medicines governance
- E-prescribing and administration
- Support the safe and efficient delivery of chemotherapy
- Multidisciplinary
- Effective data recording and report generation
- Support HSE and DOH EPR and eHealth programmes
Rank Order of Error Reduction Strategies

- Forcing functions and constraints
- Automation and computerization ✓
- Simplify and standardize ✓
- Reminders, check lists and double check systems ✓
- Rules and policies ✓
- Education and Information ✓
People and Quality

- Diligence
- Do right
- Ingenuity

- Positive deviance
  - disruption
- Build on capability